ATE497698T1 - Proteaseresistentes ti-wachstumshormon freisetzendes hormon - Google Patents

Proteaseresistentes ti-wachstumshormon freisetzendes hormon

Info

Publication number
ATE497698T1
ATE497698T1 AT03793134T AT03793134T ATE497698T1 AT E497698 T1 ATE497698 T1 AT E497698T1 AT 03793134 T AT03793134 T AT 03793134T AT 03793134 T AT03793134 T AT 03793134T AT E497698 T1 ATE497698 T1 AT E497698T1
Authority
AT
Austria
Prior art keywords
proteas
resistant
hormone
growth hormone
growth
Prior art date
Application number
AT03793134T
Other languages
English (en)
Inventor
Ruxandra Draghia-Akli
Marta Fiorotto
George Taffet
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Application granted granted Critical
Publication of ATE497698T1 publication Critical patent/ATE497698T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03793134T 2002-08-21 2003-08-19 Proteaseresistentes ti-wachstumshormon freisetzendes hormon ATE497698T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/166,356 US20040192593A1 (en) 1999-07-26 2002-08-21 Protease resistant ti-growth hormone releasing hormone
PCT/US2003/025975 WO2004018697A2 (en) 2002-08-21 2003-08-19 Protease resistant ti-growth hormone releasing hormone

Publications (1)

Publication Number Publication Date
ATE497698T1 true ATE497698T1 (de) 2011-02-15

Family

ID=31946206

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03793134T ATE497698T1 (de) 2002-08-21 2003-08-19 Proteaseresistentes ti-wachstumshormon freisetzendes hormon

Country Status (8)

Country Link
US (1) US20040192593A1 (de)
EP (1) EP1573046B1 (de)
AR (1) AR040891A1 (de)
AT (1) ATE497698T1 (de)
AU (1) AU2003265499A1 (de)
DE (1) DE60336011D1 (de)
TW (1) TWI331156B (de)
WO (1) WO2004018697A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002348417B9 (en) * 2001-10-26 2010-02-04 Baylor College Of Medicine A composition and method to alter lean body mass and bone properties in a subject
EP1539959A2 (de) * 2002-09-18 2005-06-15 Centre Hospitalier de l'Université de Montréal (CHUM) Ghrh-analoge
US7846720B2 (en) * 2005-01-26 2010-12-07 Vgx Pharmaceuticals, Inc. Optimized high yield synthetic plasmids
US20100267635A1 (en) * 2009-04-20 2010-10-21 Theratechonolgies Inc. Use of protease inhibitors and grf molecules in combination therapy
EP2421548A4 (de) * 2009-04-20 2012-09-26 Theratechnologies Inc Verwendung von (hexenoyl-trans-3)hgrf(l-44)nh2 und simvastatin in einer kombinationstherapie
EP2841572B1 (de) 2012-04-27 2019-06-19 Duke University Genetische korrektur mutierter gene
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
US12214054B2 (en) 2015-11-30 2025-02-04 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
EP3443081A4 (de) 2016-04-13 2019-10-30 Duke University Crispr/cas9-basierte repressoren zur in-vivo-ausschaltung von gen-targets und verfahren zur verwendung
JP7490211B2 (ja) 2016-07-19 2024-05-27 デューク ユニバーシティ Cpf1に基づくゲノム編集の治療適用
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
CA3099958A1 (en) 2018-04-16 2019-10-24 The Trustees Of The University Of Pennsylvania Compositions and methods for treating duchenne muscular dystrophy
TWI887234B (zh) 2019-04-14 2025-06-21 美國公爵大學 治療杜興氏(duchenne)肌肉失養症之大型突變熱點之aav載體介導之刪除
CN112266924A (zh) * 2020-01-03 2021-01-26 浙江理工大学绍兴生物医药研究院有限公司 一种利用大肠杆菌高效表达并分泌人生长激素的方法
CA3260237A1 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression
WO2025221969A2 (en) 2024-04-18 2025-10-23 Sarepta Therapeutics, Inc. Genetic constructs for gene editing
WO2026074494A1 (en) 2024-10-03 2026-04-09 Sarepta Therapeutics, Inc. Modified viral capsids and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4233020A (en) * 1979-03-13 1980-11-11 Owens-Corning Fiberglas Corporation Collapsible mandrel
US4223021A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) * 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4224316A (en) * 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
US5134120A (en) * 1984-08-03 1992-07-28 Cornell Research Foundation, Inc. Use of growth hormone to enhance porcine weight gain
US5036045A (en) 1985-09-12 1991-07-30 The University Of Virginia Alumni Patents Foundation Method for increasing growth hormone secretion
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
US4833166A (en) * 1987-05-01 1989-05-23 Grosvenor Clark E Growth hormone releasing hormone complementary peptides
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
USRE33699E (en) * 1987-07-09 1991-09-24 International Minerals & Chemical Corp. Growth hormone-releasing factor analogs
FR2622455B1 (fr) * 1987-11-04 1991-07-12 Agronomique Inst Nat Rech Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US5023322A (en) * 1988-08-31 1991-06-11 Mta Kutatas-Es Szervezetelemzo Intezete Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
US5084442A (en) * 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5756458A (en) * 1989-06-16 1998-05-26 Pharmacia & Upjohn Company Stabilized potent GRF analogs
US5137872A (en) * 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
NZ238748A (en) * 1990-06-29 1993-09-27 Hoffmann La Roche Growth hormone releasing factor (grf) analogues
US5486505A (en) * 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
CA2084061A1 (en) * 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5792747A (en) * 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
CA2218173A1 (en) * 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
CA2297375A1 (en) * 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use
KR20020047096A (ko) * 1999-07-26 2002-06-21 크로커 사무엘 에스 초활성 돼지 성장 호르몬 분비 호르몬 유사체
WO2001066149A2 (en) * 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
AU2002348417B9 (en) * 2001-10-26 2010-02-04 Baylor College Of Medicine A composition and method to alter lean body mass and bone properties in a subject

Also Published As

Publication number Publication date
AU2003265499A1 (en) 2004-03-11
EP1573046A2 (de) 2005-09-14
US20040192593A1 (en) 2004-09-30
WO2004018697A3 (en) 2006-02-16
DE60336011D1 (de) 2011-03-24
EP1573046B1 (de) 2011-02-09
WO2004018697A2 (en) 2004-03-04
TW200416226A (en) 2004-09-01
EP1573046A4 (de) 2007-05-02
AR040891A1 (es) 2005-04-20
TWI331156B (en) 2010-10-01

Similar Documents

Publication Publication Date Title
DK1542716T3 (da) Væksthormonfrigivende peptider
NO20042182L (no) Kjemisk-modifiserte veksthormonkonjugater
ATE390898T1 (de) Zwischenwirbelimplantat
ATE394087T1 (de) Zwischenwirbelimplantat
ATE394086T1 (de) Zwischenwirbelimplantat
DE60312054D1 (de) Prothese
DE60327764D1 (de) Anti-reflux harnleiter-stents
DK1524272T3 (da) Væksthormonsekretionsfremmere
DE60336011D1 (de) Proteaseresistentes ti-wachstumshormon freisetzendes hormon
ATE496940T1 (de) Ghrelin-analoga
DE60313015D1 (de) Künstlicher satellit
DE60311192D1 (de) Bildempfangsmaterial
EP1500603A4 (de) Ausgiessbehälter
DK1548110T3 (da) Transglutaminase-producerende stamme
FR2843017B1 (fr) Implant inter-somatique
GB0222700D0 (en) Rodent trap
EP1483963A4 (de) Falscher köder
NO20023199L (no) Punktmater
ATA4422002A (de) Ausleger
FI20020655A0 (fi) Astia
NL1022386A1 (nl) Palengrijper.
GB0314413D0 (en) Bait bucket
ATA10802002A (de) Verkürzungshaken
ATE520370T1 (de) Verbesserungen bezüglich stents
UA7573S (uk) Сечоприймач

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties